Simulations Plus
Simulations Plus develops mechanistic and AI-enabled modeling and simulation software (PBPK, PK/PD, QSP, QST, ADMET) for pharmaceutical and biotechnology drug development, serving 280+ clients including 19 of the top 20 global pharma companies via enterprise licensing, consulting services, and clinical trial training.
- Company typePublic
- Founded1996
- HeadquartersLancaster, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Simulations Plus does
Simulations Plus, Inc. (NASDAQ: SLP) is a 1996-founded developer of modeling and simulation software for pharmaceutical and biotechnology drug development, headquartered in Research Triangle Park, Durham, North Carolina. The company builds mechanistic and AI-enabled platforms spanning the full drug development continuum: GastroPlus for PBPK/PBBM absorption modeling, MonolixSuite for population PK/PD pharmacometrics, ADMET Predictor for ML-based ADMET property prediction (175+ properties), DILIsym for quantitative systems toxicology (drug-induced liver injury), Thales for quantitative systems pharmacology, and the Pro-ficiency platform (acquired June 2024 for ~$100M) for clinical trial training and performance management. The portfolio is complemented by add-on modules (MedChem Designer, MembranePlus, DDDPlus, IVIVCPlus, PBPKPlus, PDPlus, PKPlus), disease-specific QSP library models (OBESITYsym, NAFLDsym, IPFsym, ILDsym, etc.), and consulting service packages (Consult + Coach, First-in-Human Simulator, Pulmonary Package, NAMVantage).
The company monetizes through enterprise annual site licensing (per-seat and site-wide subscriptions) and a consulting services practice staffed by pharmacometricians and regulatory experts. Roughly 60% of revenue is recurring software licensing and approximately 40% is professional services, with software revenue of ~$14.6M and services revenue of ~$9.7M in Q2 FY2026. Go-to-market is primarily enterprise direct sales complemented by an event-driven motion (ACoP, ISSX, ACCP, DPHARM, AAPS), a self-serve evaluation program, a University+ academic program, and a Consult + Coach bundle that ties free 3-month software trials to consulting engagements. The company reports 280+ active customers, including 19 of the top 20 global pharmaceutical companies, and operates across North America, Europe, and Asia.
Strategic positioning rests on validated mechanistic models developed over 30+ years, seven concurrent FDA-funded research collaborations, and fourteen regulatory agencies trained on its software. The company is investing in an AI-native Composer platform built with NVIDIA BioNeMo Agent Toolkit and CUDA-optimized nvQSP solvers, and in 2026 entered strategic AI collaboration programs with three large pharmaceutical companies and a co-development partnership with Lonza and the U.S. FDA. Simulations Plus has entered a definitive agreement to be acquired by healthcare-focused private equity firm Altaris, LLC for approximately $375 million ($18.50 per share) in an all-cash transaction expected to close in Q4 2026, at which point the company will be combined with Altaris portfolio company Chemical Computing Group and become privately held.
Simulations Plus firmographics
Firmographics- Name
- Simulations Plus
- Legal name
- Simulations Plus, Inc.
- Website
- https://simulations-plus.com
- Company type
- Public
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Simulations Plus develops mechanistic and AI-enabled modeling and simulation software (PBPK, PK/PD, QSP, QST, ADMET) for pharmaceutical and biotechnology drug development, serving 280+ clients including 19 of the top 20 global pharma companies via enterprise licensing, consulting services, and clinical trial training.
- Ownership category
- akta.pro rank
Simulations Plus industry classification
Industry- Product category
- Pharmaceutical R&D Modeling and Simulation Software
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Computer Systems Design and Related Services (54151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where Simulations Plus is headquartered
LocationHeadquarters
- HQ city
- Lancaster
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Simulations Plus business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Licensing: Recurring software licensing of flagship simulation platforms including GastroPlus, MonolixSuite, ADMET Predictor, DILIsym, Thales, and Pro-ficiency. Revenue is recurring in nature with annual renewal cycles. Software revenue represented approximately 60% of total revenue in Q2 2026 at $14.6 million.
- Consulting Services: Consulting engagements staffed by pharmacometricians and regulatory experts providing services across discovery, development, clinical operations, and commercialization phases. Services revenue represented approximately 40% of total revenue in Q2 2026 at $9.7 million, growing 8% year-over-year.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise site license with annual subscription |
| Per seat | Annual | Individual user seats |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels7 records
Simulations Plus product offering
Product offeringCore offering
Simulations Plus develops and licenses computational modeling and simulation software (GastroPlus, MonolixSuite, ADMET Predictor, DILIsym, Thales, Pro-ficiency) for pharmaceutical and biotechnology drug discovery, development, and clinical operations. The company also provides complementary consulting services staffed by pharmacometricians and regulatory scientists, covering discovery through commercialization phases, including specialized packages such as Consult + Coach, First-in-Human Simulator, NAMVantage, and the Pulmonary Package.
Product overview
Simulations Plus offers a comprehensive portfolio of model-informed drug development (MIDD) software and services spanning discovery through commercialization. The core product suite includes GastroPlus® (PBBM/PBPK absorption and pharmacokinetics modeling), MonolixSuite™ (population PK/PD pharmacometrics), ADMET Predictor® (AI/ML-based ADMET property prediction), DILIsym® (Quantitative Systems Toxicology for liver injury), Thales™ (Quantitative Systems Pharmacology platform), and Pro-ficiency® (clinical trial training and performance management, acquired 2024). These are complemented by specialized add-on modules (MedChem Designer, MembranePlus, DDDPlus, P-PSD), disease-specific QSP library models (OBESITYsym, NAFLDsym, IPFsym, ILDsym, etc.), and consulting service packages (Consult + Coach, Pulmonary Package, NAMVantage). The company is developing an AI-native Composer platform integrating mechanistic modeling with agentic AI capabilities via NVIDIA BioNeMo. Services include Discovery, Development, Clinical Operations, and Commercialization consulting, supported by training programs and workshops.
Differentiator
Problem solved
Functional benefit
Brands
- GastroPlus: Mechanistically based simulation software for PBPK/PBBM modeling of drug absorption and pharmacokinetics
- MonolixSuite
- ADMET Predictor
- DILIsym
- Thales
- Pro-ficiency
Products and services
- GastroPlus®
Quantifiable outcome
- Up to 75% reduction in time required for end-to-end QSP modeling
- +2 more outcomes
Companies that use Simulations Plus
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Simulations Plus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability8 records
Feature10 records
Simulations Plus partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Chemical Computing GroupcoreUpon closing of the Altaris acquisition, Simulations Plus will be combined with Chemical Computing Group (an existing Altaris portfolio company providing advanced molecular design software) to create an integrated platform for AI-driven drug development and molecular design.
- NVIDIAcoreTechnical collaboration to enable GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications in drug development. Combines Simulations Plus validated scientific engines (PBPK, PK/PD, QSP) with NVIDIA AI infrastructure including BioNeMo platform. Testing shows up to 75% reduction in time required for end-to-end QSP modeling.
- LonzacoreFunded research collaboration with U.S. FDA to develop and validate mechanistic predictive framework for amorphous solid dispersion (ASD) drug products. Lonza leads experimental work while Simulations Plus develops IVIVE frameworks using DDDPlus and GastroPlus platforms to support virtual bioequivalence assessments.
- U.S. FDAcoreOngoing research collaboration to advance predictive frameworks for drug products and food chemical safety assessments. FDA provides funding and curated toxicological datasets for training and validation of AI/ML safety models. Supports model-informed drug development and new approach methodologies (NAMs).
- Three Large Pharmaceutical CompaniescoreStrategic collaboration programs to advance AI-enabled workflows across the drug development lifecycle. Programs integrate Simulations Plus AI agents into model-informed drug development workflows using GastroPlus, MonolixSuite, ADMET Predictor, and Thales platforms, enabling natural language interaction and automated data processing.
- Eli LillycoreCollaboration on AI-driven drug discovery mentioned as contributing to strategic positioning and stock performance, indicating active partnership in advancing AI-enabled drug development.
- National Institute of Environmental Health Sciences (NIEHS)minorExtended collaboration applying Simulations Plus software engines to help design, validate, and benchmark new experimental systems for chemical safety evaluation. Part of national effort to modernize chemical risk assessment through new approach methodologies.
- University of BathminorJoint recipient of FDA grant recognizing and supporting collaborative work in model-informed drug development.
- University of PittsburghminorResearch partnership for development and validation of BIOLOGXsym software for macromolecule liver safety assessment, integrating human-on-a-chip systems for improved drug safety evaluation.
- University of North CarolinaminorResearch partnership for development and validation of BIOLOGXsym software for macromolecule liver safety, expanding quantitative systems toxicology applications to biologics and gene therapies.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
Simulations Plus competitors and assessment
Company assessmentDirect peers
- Certara: Certara is the most direct competitor, offering biosimulation software (GastroPlus's primary competitor for PBPK), regulatory science consulting, and model-informed drug development services to the same pharmaceutical and biotech customer base.
- Schrödinger: Schrödinger provides physics-based and AI-driven molecular simulation software for drug discovery, overlapping with ADMET Predictor and MedChem Designer and targeting similar pharmaceutical computational chemistry and discovery customers.
- Chemical Computing Group (CCG / MOE): CCG develops the Molecular Operating Environment (MOE) platform for drug discovery and molecular design; it is being combined with Simulations Plus under Altaris and competes directly with ADMET Predictor and MedChem Designer in cheminformatics.
Broad incumbents
- Dotmatics: Dotmatics offers a broad scientific R&D informatics platform (LIMS, ELN, data management) for pharma/biotech, providing overlapping data infrastructure for model-informed drug development customers.
- Instem (now part of Perceptive): Instem/Perceptive provides life science R&D software including preclinical informatics, regulatory submissions, and study management — adjacent to Simulations Plus's preclinical and regulatory modeling offerings.
Emerging players
- Genedata: Genedata provides enterprise informatics platforms for biopharma R&D (screening, biologics, biomarker analysis), serving similar pharma/biotech customers with workflow software that complements mechanistic modeling.
- OpenEye Scientific (Cadence Design Systems): OpenEye develops molecular modeling and cheminformatics software (e.g., OMEGA, FEP+) used in drug discovery, overlapping with Simulations Plus's ADMET Predictor and computational chemistry offerings.
- Insilico Medicine: Insilico Medicine is an AI-native drug discovery company using generative AI and end-to-end platforms to compete for pharma R&D spend that historically went to traditional PBPK/QSP modeling vendors.
- Recursion Pharmaceuticals: Recursion applies AI-driven phenotypic screening and high-throughput biology to drug discovery, representing an AI-native alternative approach that competes for pharma R&D budget allocated to model-informed discovery.
Others
- L7 Informatics: L7 Informatics provides data and workflow platforms for biopharma R&D and manufacturing; it serves as an enabling informatics layer adjacent to Simulations Plus's MIDD-focused modeling and consulting business.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Simulations Plus social profiles
Digital presenceSimulations Plus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Simulations Plus leadership team
Management profileNumber of profiles
Profiles16 records
Simulations Plus subsidiaries and ownership
Company hierarchySubsidiaries1 record
Simulations Plus funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Simulations Plus M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Simulations Plus
What does Simulations Plus do?
Simulations Plus develops and licenses computational modeling and simulation software (GastroPlus, MonolixSuite, ADMET Predictor, DILIsym, Thales, Pro-ficiency) for pharmaceutical and biotechnology drug discovery, development, and clinical operations. The company also provides complementary consulting services staffed by pharmacometricians and regulatory scientists, covering discovery through commercialization phases, including specialized packages such as Consult + Coach, First-in-Human Simulator, NAMVantage, and the Pulmonary Package.
Is Simulations Plus a public or private company?
Simulations Plus is a public company. It is classified as public and is currently operating.
When was Simulations Plus founded?
Simulations Plus was founded in 1996. It employs 101 to 250 people.
Where is Simulations Plus based?
Simulations Plus is headquartered in Lancaster, United States, in the North America region.
How does Simulations Plus make money?
Two revenue lines are on record. Software Licensing is the primary driver. The others are consulting Services.
Who are Simulations Plus's main competitors?
Direct peers on record are Certara, Schrödinger and Chemical Computing Group (CCG / MOE). Broad incumbents are Dotmatics and Instem (now part of Perceptive). Emerging players are Genedata, OpenEye Scientific (Cadence Design Systems), Insilico Medicine and Recursion Pharmaceuticals. L7 Informatics is listed as an others.
Does Simulations Plus have an API?
Yes. GPX (GastroPlus X.2) includes REST API capabilities for workflow automation, allowing users to build, execute, and manipulate GPX projects programmatically and access external computational engines. The API enables automating workflows, integrating with external systems, and enabling complex reporting and plotting functionality.
What industry is Simulations Plus in?
Simulations Plus's product category is Pharmaceutical R&D Modeling and Simulation Software. Its primary akta.pro industry code is HLAIALAG, Clinical Pharmacology & Pharmacometrics (Modeling & Simulation), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5417 and its SIC code is 8731.